Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Doseeva, Victoria ^a   Colpitts, Tracey ^b   Gao, Grace ^a   Woodcock, Juliana ^a   Knezevic, Vladimir ^a  

^a 20/20 GeneSystems 9430 Key West Avenue ^*  (United States)

^b Abbott Molecular Inc   (United States)

Author keywords

Autoantibodies; Biomarkers; Blood test; Early detection; Lung cancer (LC); Tumor proteins

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NY ESO 1 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOLOGY TEST KIT; INTERMETHOD COMPARISON; LARGE CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; PREDICTION; PROTEIN ASSAY UTILIZING LUNG CANCER ANALYTE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; VALIDATION PROCESS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; DEMOGRAPHY; EARLY CANCER DIAGNOSIS; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY;

AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DEMOGRAPHY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOASSAY; LUNG NEOPLASMS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84924287251     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0419-y     Document Type: Article

References (72)

1. American Cancer Society. Cancer Facts and Figures 2014. Atlanta, GA. ( http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/ )
2. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008;57(45):1226-8.
3. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351-64. doi:10.1056/NEJMsa1211127.
4. US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2014.
5. Mantovani C, Novello S, Ragona R, Beltramo G, Giglioli FR, Ricardi U. Chemo-radiotherapy in lung cancer: state of the art with focus on the elderly population. Ann Oncol. 2006;17 Suppl 2:ii61-63.6.
6. Wender R, Fontham ET, Barrera Jr E, Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107-17. doi:10.3322/caac.21172.
7. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409. doi:10.1056/NEJMoa1102873.
8. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-29. doi:10.1001/jama.2012.552.
9. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7:212-22.
10. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-84.
11. Patz Jr EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269-72.
12. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A. Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med. 2013;11:168.
13. Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S, Agrawal A. Lung cancer biomarkers: State of the art. J Carcinog. 2013;12:3. doi:10.4103/1477-3163.107958.
14. Zhang Y, Yang D, Weng L, Wang L. Early Lung Cancer Diagnosis by Biosensors. Int J Mol Sci. 2013;14(8):15479-509. doi:10.3390/ijms140815479.
15. Tsay JC, DeCotiis C, Greenberg AK, Rom WN. Current readings: blood-based biomarkers for lung cancer. Semin Thorac Cardiovasc Surg. 2013;25(4):328-34. doi:10.1053/j.semtcvs.2013.11.001.
16. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila). 2012;5(8):992-1006. doi:10.1158/1940-6207.
17. Crosbie PAJ, Shah R, Summers Y, Dive C, Blackhall F. Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. Transl Lung Cancer Res. 2013;2(5):382-97.
18. Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013;108(5):327-33. doi:10.1002/jso.23382.
19. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24(4):209-18.
20. Patz Jr EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon 2nd JE. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007;25(35):5578-83.
21. Sun N, Chen Z, Tan F, Zhang B, Yao R, Zhou C, et al. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. 2013 Sep 15;19(18):5136-45. doi:10.1158/1078-0432.CCR-13-0046
22. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng Y-L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103(14):1112-22. doi:10.1093/jnci/djr216.
23. Li X, Asmitananda T, Gao L, Gai D, Song Z, Zhang Y, et al. Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma. 2012;59(5):500-7. doi:10.4149/neo_2012_064.
24. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One. 2010;7:5(12).
25. Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, et al. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics. 2014;11:32.
26. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, et al. Diagnostic accuracy of MALDI mass spectrometricanalysis of unfractionated serum in lung cancer. J Thorac Oncol. 2007;2:893-901.
27. Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev. 2012;21(5):786-92. doi:10.1158/1055-9965.EPI-11-0932.
28. Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, Lokshin AE, et al. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. Thorac Oncol. 2012;7(4):698-708.
29. Izbicka E, Streeper RT, Michalek JE, Louden CL, Diaz 3rd A, Campos DR. Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics. 2012;9(1):27-35.
30. Yonemori K, Tateishi U, Uno H, Yonemori Y, Tsuta K, Takeuchi M, et al. Development and validation of diagnostic prediction model for solitary pulmonary nodules. Respirology. 2007;12(6):856-62.
31. Beane J, Sebastiani P, Whitfield TH, Steiling K, Dumas YM, Lenburg ME, et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila). 2008;1(1):56-64. doi:10.1158/1940-6207.CAPR-08-0011.
32. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013;5(207):207ra142. doi:10.1126/scitranslmed.3007013.
33. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276(23):6880-904. doi:10.1111/j.1742-4658.2009.07396.
34. Desmetz C, Mange A, Maudelonde T, Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med. 2011;15(10):2013-24. doi:10.1111/j.1582-4934.2011.01355.x.
35. Leidinger P, Keller A, Heisel S, Ludwig N, Rheinheimer S, Klein V, et al. Identification of lung cancer with high sensitivity and specificity by blood testing. Respir Res. 2010;11:18. doi:10.1186/1465-9921-11-18.
36. Jia J, Wang W, Meng W, Ding M, Ma S, Wang X. Development of a multiplex autoantibody test for detection of lung cancer. PLoS One. 2014;9(4):e95444. doi:10.1371/journal.pone.0095444.
37. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol. 2006;1(6):513-9.
38. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci O, et al. Autoantibodies in lung cancer-possibilities for early detection and subsequent cure. Thorax. 2008;63(3):228-33. doi:10.1136/thx.2007.83592.
39. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26(31):5060-6. doi:10.1200/JCO.2008.16.2388.
40. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98(17):9824-9.
41. Pereira-Faca SR, Kuick R, Puravs E, Zhang Q, Krasnoselsky AL, Phanstiel D, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res. 2007;67(24):12000-6.
42. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010;16:3452-62. doi:10.1158/1078-0432.ccr-09-3192.
43. Murray A, Chapman CJ, Healey G, Peek LJ, Parsons G, Baldwin D, et al. Technical validation of an autoantibody test for lung cancer. Ann Oncol. 2010;21(8):1687-93. doi:10.1093/annonc/mdp606.
44. Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4(7):1126-34. doi:10.1158/1940-6207.CAPR-10-0328.
45. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011;22(2):383-9. doi:10.1093/annonc/mdq361.
46. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: Improved clinical utility through additional autoantibody assays. Tumour Biol. Tumour Biol. 2012;33(5):1319-26. doi:10.1007/s13277-012-0379-2.
47. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285-93.
48. Colpitts T, Russell E, Frost S, Ramirez J, Singh B, Russell JC. Methods and marker combinations for screening for predisposition to lung cancer. US20070178504 (2007) & US20080160546. 2008.
49. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059-68.
50. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler Jr GB, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultra-structural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529-53.
51. Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53(1):61-6.
52. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al. CYFRA 21-1: a new marker in lung cancer. Cancer. 1993;72(3):707-13.
53. Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the First European Multicentre Evaluation. Eur J Cancer. 1994;30A(5):601-6.
54. Brechot JM, Chevret S, Nataf J, Le Gall C, Fretault J, Rochemaure J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumor markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997;33(3):385-91.
55. Ono A, Takahashi T, Mori K, Akamatsu H, Taira T, et al. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer. 2013;13:354. doi:10.1186/1471-2407-13-354.
56. Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, et al. CYFRA21-1 is a prognostic determinant in non-small cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90(11):2097-105.
57. Blankenburg F, Hatz R, Nagel D, Ankerst D, Reinmiedl J, Gruber C, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol. 2008;29(4):272-7. doi:10.1159/000152945.
58. Molina R, Agusti C, Filella X, Jo J, Joseph J, Giménez N, et al. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol. 1994;15:318-25.
59. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA21-1, and neuro-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48(11):1931-7.
60. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138-43. doi:10.1016/j.lungcan.2011.11.012.
61. Salgia R, Harpole D, Herndon 2nd JE, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125, and CEA in non-small cell lung cancer. Anticancer Res. 2001. Anticancer Res. 2001;21(2B):1241-6.
62. Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011;74(1):112-7. doi:10.1016/j.lungcan. 2011.02.001.
63. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004;78:216-21.
64. Bast Jr RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GBCA. CA 125: the past and the future. Int J Biol Markers. 1998;13(4):179-87.
65. Buccheri G, Ferrigno D. Lung tumour markers in oncology practice: a study of TPA and CA125. Br J Cancer. 2002;87(10):1112-8. doi:10.1038/sj.bjc.6600577.
66. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998;187(8):1349-54.
67. Türeci Ö, Mack U, Luxemburger U, Heinen H, Krummenauer F, Sester M, et al. Humoral immune responses of lung cancer patients against tumour antigen NY-ESO-1. Cancer Lett. 2006;236:64-71.
68. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2013;159(6):411-20. doi:10.7326/0003-4819-159-6-201309170-00690.
69. Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Bronchoalveolar lavage fluid level of carcinoembryonic antigen in the diagnosis of peripheral lung cancer. Monaldi Arch Chest Dis. 1995;50(3):177-82.
70. Bulut I, Arbak P, Coskun A, Balbay O, Annakkaya AN, Yavuz O, et al. Comparison of serum CA 19.9, CA 125 and CEA levels with severity of chronic obstructive pulmonary disease. Med Princ Pract. 2009;18(4):289-93. doi:10.1159/000215726.
71. Sekiya K, Sakai T, Homma S, Tojima H. Pulmonary tuberculosis accompanied by a transient increase in serum carcinoembryonic antigen level with tuberculous empyema drainage. Intern Med. 2007;46(21):1795-8.
72. Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129(5):1305-12.